DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* NOVALIX *


 

2002 - Alsace
Strasbourg-Illkirch
www.alix-pharma.com

 

Discovery, Drugs
(also Design, Protein)
Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage
Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry
Clients: Research labs
info@novalix-pharma.com

Age: 14 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC]
Sc.Dir.-CSO: Zeyer (Denis)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
Note: Alix has become, end of 2008, a subsidiary of Novalix, then Alix has been discontinued in 2009 ; no legal reports since 2006 for Novalix (and also Alix) ; Jenn (Stephan) [born 1968] is president of the company

Turnover (M€) : 0.5 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .01 Partnering R&D agreement with Teijin Pharma for a multi-target integrated drug discovery collaboration (through Graffinity) R&D [9 years]
2011 .08 Partnering R&D agreement with Galapagos in osteoarthritis (through Graffinity) R&D [8 years]
2011 .03 Partnering R&D agreement with Shionogi (through Graffinity) R&D [8 years]
2010 .11 Acquisition of Graffinity (Germany), with proprietary fragment-based SPR drug discovery technology ACQ+ [7 years]
2009 .01 Partnering R&D agreement with Sosho, an Osaka university spin-off, for protein structure determination of intractable targets R&D [6 years]
2008 .10 Acquisition of Novalix (by merger and integration), a contract research biotech company (60 employees) specialised in protein production and cristallography analysis [company renamed as NovaliX and AliX name discontinued in 2011] ACQ+ [5 years]
2008 .09 Nomination : Denis Zeyer, new CEO, replacing Jean-Paul Renaud, back to academic activities ORGN [5 years]
2002 .11 Company founded as AliX by Jean-Paul Renaud, Jean Cavarelli, Dino Moras, Olivier Poch, Marc Ruff, Jean-Claude Thierry, Jean-Marie Wurtz, and Marat Yusupov, as a spin-off from the Department of Structural Biology and Genomics (DBGS) of the Institute of Genetics and Molecular and Cellular Biology (IGBMC) ORGF [0 year]

Actualisation / Updating: 26-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende